ニードルフリーインジェクションシステム市場：技術別（ジェット、スプリング、マイクロアレイパッチ）、製品別（プレフィルド、フィラブル）、薬剤タイプ別（液体、粉末）、アプリケーション別（ワクチン、皮膚科）、エンドユーザー別（病院、在宅医療）-2026年までの世界市場予測

Needle-Free Injection System Market by Technology (Jet, Spring, Micro-array Patch), by Product (Prefilled, Fillable), Type of Medication (Liquid, Powder), Application (Vaccination, Dermatology), End Users (Hospital, Homecare) - Global Forecast to 2026

MarketsandMarketsは、無針注射器市場は2020年から2026年にかけてCAGR17.0%で、2021年の1億2400万米ドルから2026年には2億7200万米ドルに達すると予測しています。この市場の成長は、主に技術の進歩、自己注射装... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年2月15日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	232	219	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

MarketsandMarketsは、無針注射器市場は2020年から2026年にかけてCAGR17.0%で、2021年の1億2400万米ドルから2026年には2億7200万米ドルに達すると予測しています。この市場の成長は、主に技術の進歩、自己注射装置の需要の増加、慢性疾患の発生率の上昇によってもたらされます。老年人口の増加や慢性疾患の蔓延に伴い、患者数は世界的に大幅に増加しています。このため、針のない注射器の使用など、高度で効果的な治療方法に対する需要が高まっています。さらに、先進的な薬物送達技術の採用が世界的に進んでいることも、この市場の成長を支えています。一方、大量投与や静脈内投与システムによる制約が、市場の成長を抑制する主な要因となっています。
本レポートでは、無針注射器市場を製品、タイプ、用途、技術、送達部位、エンドユーザー、地域別に分類しています。
"充填式無針注射器セグメントが無針注射器システム市場で最大のシェアを占めている。"
製品に基づき、ニードルフリー注射システム市場は、充填可能なニードルフリー注射器とプレフィルド・ニードルフリー注射器に区分けされます。2020年、ニードルフリー注射システム市場では、充填式ニードルフリー注射器が63.4%と大きなシェアを占めています。この製品セグメントは、予測期間中に17.7%のCAGRで、2021年の7940万ドルから2026年には1億7970万ドルに達すると予測される。このセグメントの大きなシェアは、ワクチン接種、インスリン、その他の薬物送達におけるニードルフリー注射の用途が増加していることに起因しています。
"ジェットベースのニードルフリー注射器セグメントがニードルフリー注射器市場で最大のシェアを占めました。"
技術に基づいて、ニードルフリー注射システム市場は、ジェットベース、スプリングベース、マイクロアレイパッチ、およびその他の注射器にセグメント化することができます。2020年には、ジェットベースの無針注射器セグメントが、世界の無針注射システム装置市場の技術別シェアで67.4%と最大のシェアを占めると予想されます。この分野は、予測期間中にCAGR18.3%で、2020年の7140万米ドルから2026年には1億9690万米ドルに達すると予測されます。このセグメントの大きなシェアは、迅速な薬剤投与、投与量の正確性の向上、組織への拡散性の向上、反応速度の向上など、この技術に関連する利点に起因するものだと考えられます。

" 無針注射器市場において、液体ベースの注射器セグメントが最大のシェアを占めました。"
無針注射システム市場は、タイプにより、液体ベース、粉末ベース、投射/デポベースの無針注射器に区分されます。液体ベースのセグメントは、2020年のニードルフリー注射システム市場で70.9%の最大シェアを占めています。このセグメントの大きなシェアは、皮膚や薬物分子の完全性を傷つけることなく、皮膚やその下の脂肪層に浸透するのに十分な強度を持つ液体ジェットの能力に起因していると考えられる。
"皮下注射器セグメントがニードルフリー注射システム市場で最大のシェアを占めた"
送達部位に基づき、ニードルフリー注射システム市場は、皮下、筋肉内、皮内に区分されます。2020年には、皮下注射器セグメントが無針注射システム市場の送達部位別最大シェア48％を占めると推定されます。このセグメントの高い成長は、薬剤が注入されると毛細血管に移動し、そこから血流に運ばれるため、より高い効果が得られることに起因しています。

"無針注射器市場において充填可能なセグメントが最大のシェアを占めた。"
無針注射システム市場は、用途に基づき、ワクチンデリバリー、インスリンデリバリー、腫瘍、疼痛管理、皮膚科、その他の用途に区分されます。2020年には、ワクチンデリバリーが無針注射システム市場の用途別最大シェア32.8%を占めると推定されます。世界的な慢性疾患や感染症の蔓延が検討年のワクチン接種の需要を高めており、患者中心のケアに対する需要の高まりが、ニードルフリー注射器市場の用途別成長を促進する主な要因となっています。
"無針注射システム市場では、病院・診療所セグメントが最大のシェアを占めた。"
エンドユーザーに基づいて、ニードルフリー注射器市場は、病院＆クリニック、ホームケア環境、研究所、製薬・バイオテクノロジー企業、およびその他のエンドユーザーに区分されます。病院＆クリニックセグメントは、2020年に61.0％の最大市場シェアを占めています。技術の進歩やワクチン接種の需要増加などの要因が、病院＆クリニックセグメントの成長を後押ししている。
"ニードルフリー注射システム市場では、北米セグメントが最大のシェアを占めた。"
地域別では、ニードルフリー注射システム市場は、北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東＆アフリカに区分されます。2020年の無針注射器市場は、北米が58％の最大シェアを占め、次いで欧州、アジア太平洋地域（APAC）、中南米、中東・アフリカの順となりました。しかし、APAC地域は予測期間中に18.7%という最高のCAGRで成長すると予想されます。中国とインドにおける医療産業の急速な発展、高齢化社会の進展、平均寿命の伸び、一人当たり所得の増加、主要な市場関係者による同地域への投資の増加、民間病院・診療所の地方への拡大、製造に必要な低コストの労働力の確保、良好な規制環境の存在、自己注射器の検査需要の高まりがAPAC地域の市場成長を支えています。
主な市場参入企業:
世界の無針注射市場の有力プレイヤーには、PharmaJet（米国）、Portal Instruments（米国）、Medical International Technology, Inc（MIT）（米国）、NuGen Medical Devices（カナダ）、Crossject SA（米国）、Bioject Medical Technologies（米国）などが挙げられます。
本レポートで参照した無針注射器市場の主要参入企業（供給側）の内訳は以下の通りである。
- 企業タイプ別Tier 1-5%、Tier 2-15%、Tier 3-80%。
- 役職別Cレベル-45%, ディレクターレベル-25%, その他-30
- 地域別北米36％、欧州26％、アジア太平洋21％、中南米10％、中東・アフリカ7

調査対象範囲
この市場調査は、様々なセグメントにわたる無針注射器市場を対象としています。製品別、タイプ別、用途別、技術別、送達部位別、エンドユーザー別、地域別の様々なセグメントにおける市場規模および同市場の成長性を推定することを目的としています。また、本調査では、市場の主要企業の詳細な競合分析、企業プロフィール、製品および事業の提供に関する主な見解、最近の開発状況、主要な市場戦略についても記載しています。
レポート購入の主なメリット
本レポートは、この市場における市場リーダー/新規参入者を支援し、無針注射器市場およびそのセグメントの最も近い概算に関する情報を提供します。本レポートは、利害関係者が競争環境を理解し、自社のビジネスをより良く位置づけるための洞察を得て、適切な市場参入戦略を計画するのに役立ちます。また、市場の脈動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を得る上で、利害関係者の助けとなります。

ページTOPに戻る

Table of Contents

Summary

MarketsandMarkets expects the needle-free injection system market is projected to reach USD 272 million by 2026 from USD 124 million in 2021, at a CAGR of 17.0% from 2020 to 2026. Growth in this market is mainly driven by technological advancements, increasing demand for self-injection devices, and the rising incidence of chronic diseases. With the rising geriatric population and the increasing prevalence of chronic diseases, the patient volume has increased significantly globally. This, in turn, is creating a greater demand for advanced and effective treatment approaches, including the use of needle-free injection systems. Moreover, the high adoption of advanced drug delivery technologies across the globe is supporting the growth of this market. On the other hand, limitations with large volume and intravenous administration systems are the key factors restraining the growth of the market
In this report, the needle-free injection system market is segmented on the basis of product, type, application, technology, site of delivery, end user, and region.
“fillable needle-free injectors segment accounted for the largest share in the needle-free injection system market.”
Based on product, the needle-free injection system market is segmented into fillable and pre-filled needle-free injectors. In 2020, the fillable needle-free injectors accounted for the larger share of 63.4% of the needle-free injection system market. This product segment is projected to reach USD 179.7 million by 2026 from 79.4 million in 2021, at a CAGR of 17.7 % during the forecast period. The large share of this segment can be attributed to the increasing application of needle-free injections in vaccination, insulin, and other drug delivery.
“Jet-based needle-free injectors segment accounted for the largest share in the needle-free injection system market.”
On the basis of technology, the needle-free injection system market can be segmented into jet-based, spring-based, microarray patches and other injectors. In 2020, the jet-based needle-free injectors segment is expected to command the largest share of 67.4% of the global needle-free injection system devices market by technology. This segment is projected to reach USD 196.9 million by 2026 from USD 71.4 million in 2020, at a CAGR of 18.3% during the forecast period. The large share of this segment can be attributed to benefits associated with this technology, including rapid drug administration, improved dosage accuracy, better diffusion into the tissue, and a faster response rate.

“ liquid-based injectors segment accounted for the largest share in the needle-free injection system market.”
Based on the type, the needle-free injection system market is segmented into liquid-based, powder-based and projectile/depot-based needle-free injectors. The liquid-based segment accounted for the largest share of 70.9% of the needle-free injection system market in 2020. The large share of this segment can be attributed to the ability of a liquid jet, which is stronger enough to penetrate the skin and the underlying fat layer without harming the skin or the integrity of the drug molecule.
“subcutaneous injectors segment accounted for the largest share in the needle-free injection system market.”
Based on site of delivery, the needle-free injection system market is segmented into subcutaneous, intramuscular and intradermal. In 2020, the subcutaneous injectors segment is estimated to account for the largest share of 48% of the needle-free injection system market by the site of delivery. The higher growth of this segment is due to its greater effectiveness as the drug moves into the capillaries when it is injected and from there, it is carried to the bloodstream.

“Fillable segment accounted for the largest share in the needle-free injection system market.”
Based on applications, the needle-free injection system market is segmented into vaccine delivery, insulin delivery, oncology, pain management, dermatology, and other applications. In 2020, vaccine delivery is estimated to account for the largest share of 32.8% of the needle-free injection system market by application. The rising prevalence of chronic diseases and infectious diseases worldwide has increased the demand for vaccination in the considered year and the increasing demand for patient-centric care are the major factors driving the growth of the needle-free injection market by application.
“hospitals & clinics segment accounted for the largest share in the needle-free injection system market.”
Based on end users, the needle-free injection market is segmented into hospitals & clinics, home care settings, research laboratories, pharmaceutical and biotechnology companies, and other end users. The hospitals & clinics segment accounted for the largest market share of 61.0% in 2020. Factors such as technological advancements and an increase in demand for vaccination are driving the growth of the hospitals & clinics segment.
“North America accounted segment accounted for the largest share in the needle-free injection system market.”
On the basis of region, the needle-free injection system market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 58% of the needle-free injection market, followed by Europe, the Asia Pacific (APAC), Latin America, and the Middle East & Africa. However, the APAC region is expected to grow at the highest CAGR of 18.7% during the forecast period. The rapidly developing healthcare industry in China and India, growth in the aging population, rising life expectancy, rising per capita income, increasing investments in the region by key market players, the expansion of private-sector hospitals & clinics to rural areas, the availability of low-cost labor for manufacturing, the presence of a favorable regulatory environment, and growing demand for self-injectable devices testing are supporting market growth in the APAC region.
Key Market Players :
The prominent players in global needle-free injection market include PharmaJet (US), Portal Instruments (US), Medical International Technology, Inc (MIT) (US), NuGen Medical Devices (Canada), Crossject SA (US), and Bioject Medical Technologies (US).
A breakdown of the primary participants (supply-side) for the needle-free injection system market referred to for this report is provided below:
• By Company Type: Tier 1–5%, Tier 2–15%, and Tier 3–80%
• By Designation: C-level–45%, Director Level–25%, and Others–30%
• By Region: North America–36%, Europe–26%, Asia Pacific–21%, Latin America- 10%, and Middle East and Africa– 7%

Research Coverage:
The market study covers the needle-free injection system market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by product, by type, by application, by technology, by site of delivery, by end user, and by region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information regarding the closest approximations of the needle-free injection system market and its segments. This report will help stakeholders understand the competitive landscape, gain insights to position their businesses better, and plan suitable go-to-market strategies. The report will also help stakeholders in understanding the pulse of the market and gaining information on key market drivers, restraints, opportunities, and challenges.

ページTOPに戻る

1 INTRODUCTION 29

1.1 OBJECTIVES OF THE STUDY 29

1.2 MARKET DEFINITION 29

1.2.1 INCLUSIONS AND EXCLUSIONS 30

1.3 MARKET SCOPE 31

1.3.1 MARKETS COVERED 31

1.3.2 MARKETS COVERED–BY REGION 31

1.3.3 YEARS CONSIDERED FOR THE STUDY 32

1.4 CURRENCY 32

TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 32

1.5 STAKEHOLDERS 33

1.6 SUMMARY OF CHANGES 33

2 RESEARCH METHODOLOGY 35

2.1 RESEARCH APPROACH 35

FIGURE 1 RESEARCH DESIGN 35

2.1.1 SECONDARY DATA 36

2.1.1.1 Key data from secondary sources 37

2.1.2 PRIMARY DATA 37

2.1.2.1 Primary sources 37

2.1.2.2 Key data from primary sources 38

2.1.2.3 Breakdown of primaries 39

FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 39

2.2 MARKET SIZE ESTIMATION 39

FIGURE 3 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2020) 40

FIGURE 4 SUPPLY SIDE ANALYSIS: NEEDLE-FREE INJECTION SYSTEM MARKET 41

FIGURE 5 TOP-DOWN APPROACH 42

FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NEEDLE-FREE INJECTION SYSTEM MARKET (2021– 2026) 43

FIGURE 7 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF THE NEEDLE-FREE INJECTION SYSTEM MARKET (2020) 44

2.3 MARKET BREAKDOWN & DATA TRIANGULATION 45

FIGURE 8 DATA TRIANGULATION METHODOLOGY 45

2.4 KEY INDUSTRY INSIGHTS 46

2.5 LIMITATIONS 46

2.5.1 METHODOLOGY-RELATED LIMITATIONS 46

2.6 RISK ASSESSMENT 47

2.7 ASSUMPTIONS FOR THE STUDY 47

3 EXECUTIVE SUMMARY 48

FIGURE 9 NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2021 VS. 2026 (USD MILLION) 48

FIGURE 10 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,

2021 VS. 2026 (USD MILLION) 49

FIGURE 11 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2021 VS. 2026 (USD MILLION) 50

FIGURE 12 NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY,

2021 VS. 2026 (USD MILLION) 50

FIGURE 13 NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,

2021 VS. 2026 (USD MILLION) 51

FIGURE 14 NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2021 VS. 2026 (USD MILLION) 52

FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE NEEDLE-FREE INJECTION

SYSTEM MARKET 53

4 PREMIUM INSIGHTS 54

4.1 NEEDLE-FREE INJECTION SYSTEM MARKET OVERVIEW 54

FIGURE 16 HIGH PREVALENCE OF INFECTIOUS DISEASES, GROWING INCIDENCE OF COMMUNICABLE DISEASES DUE TO NEEDLESTICK INJURIES, AND RISE IN DEMAND FOR SELF-INJECTION DEVICES TO DRIVE MARKET GROWTH 54

4.2 ASIA PACIFIC NEEDLE-FREE INJECTION SYSTEM MARKET,

BY APPLICATION AND COUNTRY 55

FIGURE 17 VACCINATION ACCOUNTED FOR THE LARGEST SHARE IN ASIA PACIFIC 55

4.3 NEEDLE-FREE INJECTION SYSTEM MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56

FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATES DURING

THE FORECAST PERIOD 56

4.4 NEEDLE-FREE INJECTION SYSTEM MARKET: DEVELOPING VS DEVELOPED COUNTRIES 57

FIGURE 19 DEVELOPING COUNTRIES TO OFFER HIGHER GROWTH 57

4.5 REGIONAL MIX: NEEDLE-FREE INJECTION SYSTEM MARKET 57

FIGURE 20 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 57

5 MARKET OVERVIEW 58

5.1 INTRODUCTION 58

5.2 MARKET DYNAMICS: IMPACT ANALYSIS 58

5.2.1 DRIVERS 59

5.2.1.1 High prevalence of infectious diseases globally 59

FIGURE 21 PREVALENCE OF INFECTIOUS DISEASES WORLDWIDE 60

TABLE 2 PREVALENCE OF HIV WORLDWIDE (2017 VS. 2020) 61

5.2.1.2 Increasing incidence of communicable diseases due to needlestick injuries 62

5.2.1.3 Rise in demand for self-injection devices 62

5.2.1.4 Increased number of technological advancements 62

5.2.1.5 Reduction in injection system costs 63

5.2.2 RESTRAINTS 63

5.2.2.1 Higher cost of development as compared to conventional injection systems 63

5.2.2.2 Limitation with large volume and intravenous administration systems 64

5.2.3 OPPORTUNITIES 64

5.2.3.1 Rising demand for biosimilars and vaccination processes 64

5.2.3.2 Increasing number of emerging markets 64

5.2.4 CHALLENGES 65

5.2.4.1 Rise in need to ensure system sterility 65

5.2.4.2 Growth in alternative modes of drug delivery 65

5.3 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO IN NEEDLE-FREE INJECTION SYSTEM MARKET 66

FIGURE 22 IMPACT OF COVID-19 PANDEMIC ON ENTIRE NEEDLE-FREE INJECTION ECOSYSTEM (2020)- KEY HOT SPOTS OF ACTIVITY ARE HIGHLIGHTED PREVALENCE OF INFECTIOUS DISEASES WORLDWIDE 66

5.4 PRICING ANALYSIS 67

TABLE 3 AVERAGE SELLING PRICE OF NEEDLE-FREE INJECTORS IN NORTH AMERICA, BY APPLICATIONS, FOR 2020 67

5.5 SUPPLY CHAIN ANALYSIS 67

FIGURE 23 SUPPLY CHAIN ANALYSIS: NEEDLE-FREE INJECTION SYSTEM MARKET (2020) 68

5.6 PATENT ANALYSIS 69

5.6.1 PATENT PUBLICATION TRENDS FOR NEEDLE-FREE INJECTION

SYSTEM MARKET 69

FIGURE 24 GLOBAL PATENT PUBLICATION TRENDS IN NEEDLE-FREE INJECTION SYSTEM, 2016–2021 70

5.6.2 TOP APPLICANTS (COMPANIES) OF NEEDLE-FREE INJECTION SYSTEM PATENTS 70

FIGURE 25 TOP COMPANIES THAT APPLIED FOR NEEDLE-FREE INJECTION SYSTEM PATENTS, 2016–2021 70

5.6.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN NEEDLE-FREE INJECTION SYSTEM MARKET 71

FIGURE 26 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR NEEDLE-FREE INJECTION SYSTEM PATENTS, 2016–2021 71

5.7 VALUE CHAIN ANALYSIS 71

FIGURE 27 NEEDLE-FREE INJECTION SYSTEM MARKET: VALUE CHAIN ANALYSIS (2020) 72

5.8 TECHNOLOGY ANALYSIS 72

5.8.1 KEY TECHNOLOGY: JET-BASED NEEDLE-FREE INJECTORS 72

5.8.2 ADJACENT TECHNOLOGY: SPRING-BASED NEEDLE-FREE INJECTORS 72

5.8.3 MICROARRAY PATCH 72

5.8.4 OTHER TECHNOLOGIES 73

5.9 REGULATORY LANDSCAPE 73

TABLE 4 REGULATORY STANDARDS/APPROVALS REQUIRED FOR NEEDLE-FREE INJECTION PRODUCTS, BY COUNTRY/REGION 73

5.10 PORTER’S FIVE FORCES ANALYSIS 73

TABLE 5 NEEDLE-FREE INJECTION SYSTEM: PORTER’S FIVE FORCES ANALYSIS 73

5.10.1 THREAT FROM NEW ENTRANTS 74

5.10.2 COMPETITIVE RIVALRY 74

5.10.3 BARGAINING POWER OF BUYERS 75

5.10.4 BARGAINING POWER OF SUPPLIERS 75

5.10.5 THREAT FROM SUBSTITUTES 75

6 NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT 76

6.1 INTRODUCTION 77

TABLE 6 NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 77

6.2 FILLABLE NEEDLE-FREE INJECTORS 77

6.2.1 TREATMENT OF DISEASES THAT REQUIRE REGULAR ADMINISTRATION OF MEDICATION TO DRIVE MARKET GROWTH 77

TABLE 7 FILLABLE NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,

2019–2026 (USD MILLION) 78

6.3 PREFILLED NEEDLE-FREE INJECTORS 79

6.3.1 SELF-ADMINISTRATION OF DRUGS FOR TREATMENT TO DRIVE

MARKET GROWTH 79

TABLE 8 PREFILLED NEEDLE-FREE INJECTORS MARKET, BY COUNTRY,

2019–2026 (USD MILLION) 79

7 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY 80

7.1 INTRODUCTION 81

TABLE 9 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,

2019–2026 (USD MILLION) 81

7.2 JET-BASED NEEDLE-FREE INJECTORS 82

7.2.1 WIDE APPLICATIONS OF JET-BASED INJECTIONS

TO DRIVE SEGMENT GROWTH 82

TABLE 10 JET-BASED NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY,

2019–2026 (USD MILLION) 82

7.3 SPRING-BASED NEEDLE-FREE INJECTORS 83

7.3.1 LOW COST OF SPRING-BASED INJECTORS TO DRIVE MARKET GROWTH 83

TABLE 11 SPRING-BASED NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 83

7.4 MICRO-ARRAY PATCH 84

7.4.1 FUTURE DEMAND FOR VACCINES AND CONTRACEPTIVES MICRO-ARRAY PATCHES TO DRIVE MARKET GROWTH 84

TABLE 12 MICRO-ARRAY PATCH MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 84

7.5 OTHER TECHNOLOGIES 85

TABLE 13 OTHER TECHNOLOGIES NEEDLE-FREE INJECTION SYSTEM MARKET,

BY COUNTRY, 2019–2026 (USD MILLION) 85

8 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE 86

8.1 INTRODUCTION 87

TABLE 14 NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 87

8.2 LIQUID-BASED NEEDLE-FREE INJECTORS 87

8.2.1 INCREASE IN VACCINATION FOR INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 87

TABLE 15 LIQUID-BASED NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 88

8.3 POWDER-BASED NEEDLE-FREE INJECTORS 89

8.3.1 REQUIREMENT OF STABLE DRUGS TO DRIVE MARKET GROWTH 89

TABLE 16 POWDER-BASED NEEDLE FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 89

8.4 PROJECTILE/DEPOT-BASED NEEDLE-FREE INJECTORS 90

8.4.1 USE OF INERT MATERIAL OR SELF MEDICAMENT TO DRIVE MARKET GROWTH 90

TABLE 17 PROJECTILE/DEPOT-BASED NEEDLE FREE INJECTION SYSTEM MARKET,

BY COUNTRY, 2019–2026 (USD MILLION) 90

9 NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY 91

9.1 INTRODUCTION 92

TABLE 18 NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY,

2019–2026 (USD MILLION) 92

9.2 SUBCUTANEOUS NEEDLE-FREE INJECTORS 92

9.2.1 PREFERENCE FOR ADMINISTERING DELICATE DRUGS FOR INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 92

TABLE 19 SUBCUTANEOUS NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 93

9.2.2 INTRAMUSCULAR NEEDLE-FREE INJECTORS 93

9.2.2.1 Increase in vaccination requirement to drive market growth 93

TABLE 20 INTRAMUSCULAR NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 94

9.2.3 INTRADERMAL NEEDLE-FREE INJECTORS 94

9.2.3.1 Use of inert material or self medicament to drive market growth 94

TABLE 21 INTRADERMAL NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 95

10 NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION 96

10.1 INTRODUCTION 97

TABLE 22 NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,

2019–2026 (USD MILLION) 97

10.2 VACCINE DELIVERY 97

10.2.1 COST-EFFECTIVENESS AND RISE OF PREVENTIVE MEASURES TO DRIVE GROWTH IN VACCINES DELIVERY 97

TABLE 23 NEEDLE-FREE INJECTION SYSTEM MARKET FOR VACCINE DELIVERY,

BY COUNTRY, 2019–2026 (USD MILLION) 98

10.3 INSULIN DELIVERY 98

10.3.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET GROWTH 98

TABLE 24 NEEDLE-FREE INJECTION SYSTEM MARKET FOR INSULIN DELIVERY,

BY COUNTRY, 2019–2026 (USD MILLION) 99

10.4 ONCOLOGY 100

10.4.1 RISE IN CANCER PREVALENCE AND AVAILABILITY OF CANCER TREATMENT TO DRIVE MARKET GROWTH 100

TABLE 25 NEEDLE-FREE INJECTION SYSTEM MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 100

10.5 PAIN MANAGEMENT 101

10.5.1 INCREASED PREVALENCE AND TREATMENT OF CHRONIC DISEASES TO DRIVE MARKET GROWTH 101

TABLE 26 NEEDLE-FREE INJECTION SYSTEM MARKET FOR PAIN MANAGEMENT,

BY COUNTRY, 2019–2026 (USD MILLION) 101

10.6 DERMATOLOGY 102

10.6.1 INCREASED DERMATOLOGY-BASED TREATMENTS AND SURGERIES TO DRIVE MARKET GROWTH 102

TABLE 27 NEEDLE-FREE INJECTION SYSTEM MARKET FOR DERMATOLOGY,

BY COUNTRY, 2019–2026 (USD MILLION) 102

10.7 OTHER APPLICATIONS 103

TABLE 28 NEEDLE-FREE INJECTION SYSTEM MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2019–2026 (USD MILLION) 103

11 NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER 104

11.1 INTRODUCTION 105

TABLE 29 NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 105

11.2 HOSPITALS & CLINICS 106

11.2.1 INCREASING USE OF NEEDLE-LESS VACCINATION TO DRIVE ADOPTION 106

TABLE 30 NEEDLE-FREE INJECTION SYSTEM MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2019–2026 (USD MILLION) 106

11.3 HOMECARE SETTINGS 107

11.3.1 GROWING NEED FOR HOME SELF-ADMINISTRATION AND RISING GERIATRIC POPULATION TO DRIVE MARKET GROWTH 107

TABLE 31 NEEDLE-FREE INJECTION SYSTEM MARKET FOR HOMECARE SETTINGS,

BY COUNTRY, 2019–2026 (USD MILLION) 107

11.4 RESEARCH LABORATORIES 108

11.4.1 GROWING RESEARCH OF DRUG TESTING ON ANIMALS TO DRIVE MARKET GROWTH 108

TABLE 32 NEEDLE-FREE INJECTION SYSTEM MARKET FOR RESEARCH LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION) 108

11.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 109

11.5.1 INCREASING FOCUS ON BIOLOGICS DELIVERY RESEARCH TO DRIVE USAGE 109

TABLE 33 NEEDLE-FREE INJECTION SYSTEM MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 109

11.6 OTHER END USERS 110

TABLE 34 NEEDLE-FREE INJECTION SYSTEM MARKET FOR OTHER END USERS,

BY COUNTRY, 2019–2026 (USD MILLION) 110

12 NEEDLE-FREE INJECTION SYSTEM MARKET, BY REGION 111

12.1 INTRODUCTION 112

FIGURE 28 US TO DOMINATE NEEDLE-FREE INJECTION SYSTEM MARKET DURING FORECAST PERIOD 112

TABLE 35 NEEDLE-FREE INJECTION SYSTEM MARKET, BY REGION,

2019–2026 (USD MILLION) 113

12.2 NORTH AMERICA 113

FIGURE 29 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET SNAPSHOT 114

TABLE 36 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 115

TABLE 37 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 115

TABLE 38 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,

BY TECHNOLOGY, 2019–2026 (USD MILLION) 115

TABLE 39 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION) 116

TABLE 40 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,

BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 116

TABLE 41 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,

BY APPLICATION, 2019–2026 (USD MILLION) 117

TABLE 42 NORTH AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION) 117

12.2.1 US 118

12.2.1.1 US to account for the largest share of needle-free injection system market 118

TABLE 43 US: MACROECONOMIC INDICATORS 118

TABLE 44 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 119

TABLE 45 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,

2019–2026 (USD MILLION) 119

TABLE 46 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 119

TABLE 47 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY,

2019–2026 (USD MILLION) 120

TABLE 48 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,

2019–2026 (USD MILLION) 120

TABLE 49 US: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 121

12.2.2 CANADA 121

12.2.2.1 Availability of research funding and implementation of favorable government initiatives to drive market growth 121

TABLE 50 CANADA: MACROECONOMIC INDICATORS 122

TABLE 51 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 122

TABLE 52 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 123

TABLE 53 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 123

TABLE 54 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 124

TABLE 55 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 124

TABLE 56 CANADA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 125

12.3 EUROPE 125

FIGURE 30 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET SNAPSHOT 126

TABLE 57 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY,

2019–2026 (USD MILLION) 127

TABLE 58 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 127

TABLE 59 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 128

TABLE 60 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 128

TABLE 61 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 129

TABLE 62 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 129

TABLE 63 EUROPE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 130

12.3.1 GERMANY 130

12.3.1.1 Increasing demand for self-injection devices to drive market demand 130

TABLE 64 GERMANY: MACROECONOMIC INDICATORS 131

TABLE 65 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 131

TABLE 66 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 132

TABLE 67 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 132

TABLE 68 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 133

TABLE 69 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 133

TABLE 70 GERMANY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 134

12.3.2 FRANCE 134

12.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth 134

TABLE 71 FRANCE: MACROECONOMIC INDICATORS 135

TABLE 72 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 135

TABLE 73 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 136

TABLE 74 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 136

TABLE 75 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 137

TABLE 76 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 137

TABLE 77 FRANCE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 138

12.3.3 UK 138

12.3.3.1 Increasing incidence of chronic diseases and rising prevalence of obesity to drive market growth 138

TABLE 78 UK: MACROECONOMIC INDICATORS 139

TABLE 79 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 139

TABLE 80 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,

2019–2026 (USD MILLION) 140

TABLE 81 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 140

TABLE 82 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY,

2019–2026 (USD MILLION) 141

TABLE 83 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,

2019–2026 (USD MILLION) 141

TABLE 84 UK: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 142

12.3.4 ITALY 142

12.3.4.1 Increasing geriatric population and prevalence of chronic diseases to drive market growth 142

TABLE 85 ITALY: MACROECONOMIC INDICATORS 143

TABLE 86 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 143

TABLE 87 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,

2019–2026 (USD MILLION) 144

TABLE 88 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 144

TABLE 89 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 145

TABLE 90 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,

2019–2026 (USD MILLION) 145

TABLE 91 ITALY: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 146

12.3.5 SPAIN 146

12.3.5.1 Increasing prevalence of chronic diseases and technological advancement to drive market growth 146

TABLE 92 SPAIN: MACROECONOMIC INDICATORS 147

TABLE 93 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 147

TABLE 94 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,

2019–2026 (USD MILLION) 148

TABLE 95 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 148

TABLE 96 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 149

TABLE 97 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,

2019–2026 (USD MILLION) 149

TABLE 98 SPAIN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 150

12.3.6 REST OF EUROPE 150

TABLE 99 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 150

TABLE 100 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,

2019–2026 (USD MILLION) 151

TABLE 101 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 151

TABLE 102 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 152

TABLE 103 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,

2019–2026 (USD MILLION) 152

TABLE 104 ROE: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 153

12.4 ASIA PACIFIC 153

FIGURE 31 ASIA PACIFIC: NEEDLE-FREE INJECTION SYSTEM MARKET SNAPSHOT 154

TABLE 105 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY COUNTRY,

2019–2026 (USD MILLION) 155

TABLE 106 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 155

TABLE 107 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,

2019–2026 (USD MILLION) 155

TABLE 108 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 156

TABLE 109 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 156

TABLE 110 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,

2019–2026 (USD MILLION) 157

TABLE 111 APAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 157

12.4.1 JAPAN 158

12.4.1.1 Increasing geriatric population and higher adoption advance technology to drive market growth 158

TABLE 112 JAPAN: MACROECONOMIC INDICATORS 158

TABLE 113 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 158

TABLE 114 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,

2019–2026 (USD MILLION) 159

TABLE 115 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 159

TABLE 116 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 160

TABLE 117 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,

2019–2026 (USD MILLION) 160

TABLE 118 JAPAN: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 161

12.4.2 CHINA 161

12.4.2.1 Growing prevalence of lifestyle-related and chronic diseases to drive market growth 161

TABLE 119 CHINA: MACROECONOMIC INDICATORS 162

TABLE 120 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 162

TABLE 121 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,

2019–2026 (USD MILLION) 163

TABLE 122 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 163

TABLE 123 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 164

TABLE 124 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,

2019–2026 (USD MILLION) 164

TABLE 125 CHINA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 165

12.4.3 INDIA 165

12.4.3.1 Collaboration with key players in needle-free injections to drive market growth 165

TABLE 126 INDIA: MACROECONOMIC INDICATORS 166

TABLE 127 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 166

TABLE 128 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY,

2019–2026 (USD MILLION) 167

TABLE 129 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 167

TABLE 130 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 168

TABLE 131 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION,

2019–2026 (USD MILLION) 168

TABLE 132 INDIA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 169

12.4.4 REST OF ASIA PACIFIC 169

TABLE 133 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT,

2019–2026 (USD MILLION) 170

TABLE 134 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 170

TABLE 135 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 170

TABLE 136 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 171

TABLE 137 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 171

TABLE 138 ROAPAC: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER,

2019–2026 (USD MILLION) 172

12.5 LATIN AMERICA 172

TABLE 139 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 172

TABLE 140 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,

BY TECHNOLOGY, 2019–2026 (USD MILLION) 173

TABLE 141 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE,

2019–2026 (USD MILLION) 173

TABLE 142 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,

BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 174

TABLE 143 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET,

BY APPLICATION, 2019–2026 (USD MILLION) 174

TABLE 144 LATIN AMERICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY END USER, 2019–2026 (USD MILLION) 175

12.6 MIDDLE EAST & AFRICA 175

12.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TO DRIVE MARKET GROWTH 175

TABLE 145 AFRICA: MACROECONOMIC INDICATORS 176

TABLE 146 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET,

BY PRODUCT, 2019–2026 (USD MILLION) 176

TABLE 147 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET,

BY TECHNOLOGY, 2019–2026 (USD MILLION) 177

TABLE 148 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY TYPE, 2019–2026 (USD MILLION) 177

TABLE 149 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET, BY SITE OF DELIVERY, 2019–2026 (USD MILLION) 178

TABLE 150 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET,

BY APPLICATION, 2019–2026 (USD MILLION) 178

TABLE 151 MIDDLE EAST & AFRICA: NEEDLE-FREE INJECTION SYSTEM MARKET,

BY END USER, 2019–2026 (USD MILLION) 179

13 COMPETITIVE LANDSCAPE 180

13.1 OVERVIEW 180

13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 180

13.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE NEEDLE-FREE INJECTION SYSTEM MARKET 181

13.4 NEEDLE-FREE INJECTION SYSTEM MARKET RANKING 181

13.5 COMPANY EVALUATION QUADRANT 183

FIGURE 32 NEEDLE-FREE INJECTION SYSTEM MARKET: COMPANY EVALUATION MATRIX, 2020 183

13.5.1 STARS 184

13.5.2 PERVASIVE PLAYERS 184

13.5.3 EMERGING LEADERS 184

13.5.4 PARTICIPANTS 184

13.6 COMPETITIVE LEADERSHIP MAPPING FOR SMES & START-UPS 185

FIGURE 33 NEEDLE-FREE INJECTION SYSTEM MARKET: COMPANY EVALUATION MATRIX FOR SMES & START-UP 185

13.6.1 PROGRESSIVE COMPANIES 186

13.6.2 DYNAMIC COMPANIES 186

13.6.3 STARTING BLOCKS 186

13.6.4 RESPONSIVE COMPANIES 186

13.7 COMPETITIVE BENCHMARKING 186

13.7.1 OVERALL COMPANY FOOTPRINT 186

TABLE 153 OVERALL COMPANY FOOTPRINT (25 COMPANIES) 186

TABLE 154 COMPANY FOOTPRINT: BY-PRODUCTS (25 COMPANIES) 188

TABLE 155 COMPANY FOOTPRINT: BY TECHNOLOGY (25 COMPANIES) 189

TABLE 156 COMPANY FOOTPRINT: BY TYPE (25 COMPANIES) 190

TABLE 157 COMPANY FOOTPRINT: BY SITE OF DELIVERY (25 COMPANIES) 191

TABLE 158 COMPANY FOOTPRINT: BY APPLICATION (25 COMPANIES) 192

13.8 COMPETITIVE SCENARIO 193

13.8.1 PRODUCT LAUNCHES & APPROVALS 193

13.8.2 DEALS 193

TABLE 159 DEALS (2019–2021) 193

13.8.3 EXPANSIONS 194

TABLE 160 EXPANSIONS (2018) 194

14 COMPANY PROFILES 195

14.1 KEY PLAYERS 195

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

14.1.1 PHARMAJET 195

TABLE 161 PHARMAJET: BUSINESS OVERVIEW 195

14.1.2 PORTAL INSTRUMENTS 198

TABLE 162 PORTAL INSTRUMENTS: BUSINESS OVERVIEW 198

14.1.3 MEDICAL INTERNATIONAL TECHNOLOGY INC.(MIT) 200

TABLE 163 MEDICAL INTERNATIONAL TECHNOLOGY INC: BUSINESS OVERVIEW 200

14.1.4 NUGEN MEDICAL DEVICES 202

TABLE 164 NUGEN MEDICAL DEVICES: BUSINESS OVERVIEW 202

14.1.5 CROSSJECT SA 204

TABLE 165 CROSSJECT SA: BUSINESS OVERVIEW 204

14.1.6 BIOJECT MEDICAL TECHNOLOGIES INC. (ACQUIRED BY INOVIO PHARMACEUTICALS, INC.) 206

TABLE 166 BIOJECT MEDICAL TECHNOLOGIES INC.: BUSINESS OVERVIEW 206

14.1.7 ANTARES PHARMA 207

TABLE 167 ANTARES PHARMA: BUSINESS OVERVIEW 207

FIGURE 34 ANTARES PHARMA: COMPANY SNAPSHOT 208

14.1.8 INJEX PHARMA GMBH 210

TABLE 168 INJEX PHARMA GMBH: BUSINESS OVERVIEW 210

14.1.9 NATIONAL MEDICAL PRODUCTS, INC. 211

TABLE 169 NATIONAL MEDICAL PRODUCTS, INC.: BUSINESS OVERVIEW 211

14.1.10 ZEALAND PHARMA A/S. 212

TABLE 170 ZEALAND PHARMA A/S: BUSINESS OVERVIEW 212

14.2 OTHER PLAYERS 213

14.2.1 PENJET CORPORATION 213

TABLE 171 PENJET CORPORATION: BUSINESS OVERVIEW 213

14.2.2 ENESI PHARMA LIMITED 214

14.2.3 INTEGRIMEDICAL LLC 216

TABLE 173 INTEGRIMEDICAL LLC: BUSINESS OVERVIEW 216

14.2.4 AKRA DERMOJET 217

TABLE 174 AKRA DERMOJET: BUSINESS OVERVIEW 217

14.2.5 D'ANTONIO CONSULTANTS INTERNATIONAL, INC. 218

TABLE 175 D'ANTONIO CONSULTANTS INTERNATIONAL, INC: BUSINESS OVERVIEW 218

14.2.6 BASCO INDIA 219

TABLE 176 BASCO INDIA: BUSINESS OVERVIEW 219

14.2.7 MIKA MEDICAL CO. 220

TABLE 177 MIKA MEDICAL CO.: BUSINESS OVERVIEW 220

14.2.8 MADA MEDICAL PRODUCTS, INC. 221

TABLE 178 MADA MEDICAL PRODUCTS, INC.: BUSINESS OVERVIEW 221

14.2.9 VAXXAS 222

TABLE 179 VAXXAS: BUSINESS OVERVIEW 222

14.2.10 GUANGZHOU MEDSINGLONG MEDICAL EQUIPMENT CO., LTD 223

TABLE 180 GUANGZHOU MEDSINGLONG MEDICAL EQUIPMENT CO., LTD: BUSINESS OVERVIEW 223

14.2.11 QUINOVARE 224

TABLE 181 QUINOVARE: BUSINESS OVERVIEW 224

14.2.12 TAPEMARK 225

TABLE 182 TAPEMARK: BUSINESS OVERVIEW 225

14.2.13 THERAJECT 226

TABLE 183 THERAJECT: BUSINESS OVERVIEW 226

14.2.14 ZOSANO PHARMA 227

TABLE 184 ZOSANO PHARMA: BUSINESS OVERVIEW 227

14.2.15 CORIUM 228

TABLE 185 CORIUM: BUSINESS OVERVIEW 228

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX 229

15.1 DISCUSSION GUIDE 229

15.2 INDUSTRY INSIGHTS 234

15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 235

15.4 AVAILABLE CUSTOMIZATIONS 237

15.5 RELATED REPORTS 237

15.6 AUTHOR DETAILS 238

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療IT）の最新刊レポート

MarketsandMarkets社のその他分野での最新刊レポート

本レポートと同じKEY WORD（injection）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療IT）の最新刊レポート

MarketsandMarkets社のその他分野での最新刊レポート

本レポートと同じKEY WORD（injection）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?